ImaginAb

Executive Summary

ImaginAb is a pioneering US-based biotech company founded in 2007, specializing in radiopharmaceuticals and advanced imaging diagnostics. Its core technology, CD8 ImmunoPET, enables non-invasive, whole-body imaging of immune cell activity, offering a transformative alternative to repeat biopsies for monitoring treatment response in cancer and autoimmune diseases. By visualizing CD8+ T cells, the platform provides real-time insights into immune checkpoint inhibitor efficacy, potentially guiding therapy decisions and accelerating drug development. The company is currently advancing its lead candidate through Phase 3 trials, targeting regulatory approval and commercialization. With a strong intellectual property portfolio and collaborations with major pharmaceutical companies, ImaginAb is well-positioned to address the critical unmet need for non-invasive immune monitoring. The company's Phase 3 status suggests a maturing pipeline, and successful trial outcomes could lead to significant valuation inflection. However, as a private company, funding and regulatory risks remain. Overall, ImaginAb's innovative approach and clinical progress justify a conviction score reflecting its potential to disrupt diagnostic imaging in immuno-oncology.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Trial Top-Line Results for CD8 ImmunoPET in Solid Tumors65% success
• Q2 2027Regulatory Submission (BLA) for CD8 ImmunoPET in Immunotherapy Monitoring50% success
• H1 2027New Strategic Partnership or Licensing Deal with Major Pharma70% success